HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Jilin Ginseng Health Products

Jilin’s ginseng industry spans cultivation, primary processing, traditional medicine and food production, health products, personal-care ingredients, and branded retail, allowing sourcing by grade, process form, and regulated use.

Formation and regional foundations

The cluster combines Changbai Mountain growing conditions, a long cultivation tradition, processors in Ji’an and Tonghua, and provincial research and standards. It is extending from dried roots and slices into food, medicine, health products, and traceable ingredients.

Jilin ginseng begins with seed stock and forest or field cultivation, then moves through harvest, washing, drying or steaming into herbal pieces, foods, health foods, medicines or personal-care routes. One ginseng product label can span very different regulatory categories and uses. Procurement first confirms species, origin, crop year, process and product authorisation before composition and packaging.

Core geography: Changbai Mountain production–Tonghua and Ji’an processing–Changchun research and distribution

Jilin Ginseng Industry and Product Routes

Cultivation, Primary Processing, Extraction, Products and Market Interfaces

The route shows common processes and implies no shared fields, materials, formulas or channels among the three companies.

  • Seed stock, fields and standard cultivation — Records species, parcel, soil, inputs, age and harvest lot.
  • Washing, steaming, drying and grading — Controls fresh weight, temperature, moisture, visual grade and lot blending.
  • Cutting, extraction and formulation — Manages size, solvent, concentration, excipients and yield by product category.
  • Food, medicine and personal care — Separates authorisation, standard, label, use and permitted claims.
  • Composition, safety and authenticity tests — Checks species, characteristic components, residues, metals, microbes and adulteration.
  • Brand, retail and origin experience — Connects wholesale, pharmacies, retail, e-commerce, gifting and origin visits.

01 · RMB 80 Billion, Two Shares and 3,000 Products Span Different Years

Comprehensive value, output shares and product count use different denominators.

Jilin government investment information records comprehensive ginseng value above RMB 80 billion in 2024. Related public information updated in 2026 places Jilin at roughly 60 percent of Chinese output and 40 percent of world output and reports more than 3,000 developed products. The measures describe provincial scale but use different dates and objects.

Comprehensive value can cover cultivation, processing, trade and related services; output shares compare physical production; product count depends on definitions of variety, specification and current or historical development. More than 3,000 products is not 3,000 valid approvals and does not prove active production. Dividing value by product count yields no useful operating average.

The data table keeps the 2024 comprehensive-value baseline apart from the 2026 shares and product count. National and world shares also need the output definition and comparison year. Company revenue, item sales and approval status require statutory or regulatory information rather than allocation from provincial measures.

  • Retain year, geography, product definition and method for each measure.

02 · Cultivation Standards Must Continue into the Harvest Lot

Policy and industry updates set direction; field records establish material identity.

The Jilin policy for high-quality ginseng development covers cultivation, processing and branding, while agricultural updates record industry progress. Both show attention to standardisation and full-chain management. They do not provide variety, soil, inputs or seasonal yield for every parcel.

Ginseng has a long growing cycle, and parcel history, shade, moisture, disease and harvest age vary within one region. Once roots leave the soil, mixed ages or parcels can be difficult to recover from appearance. Changbai Mountain on a finished pack cannot replace cultivation records.

A cultivation lot starts with seed or seedling code and records parcel coordinates, prior crop, inputs, field work, disease treatment and harvest date. Roots are weighed by parcel and age at receipt, and transport containers and primary-processing lots retain linked codes. Material is isolated when an input record is incomplete.

  • Species, parcel, age, inputs and harvest date all matter.

03 · Provincial Trends and Jian Production Answer Different Levels

Regional development cannot replace the primary-processing record of fresh roots.

Jilin agricultural information provides province-wide ginseng developments, while Jian information focuses on its local industry. The former tracks provincial trends; the latter describes an important production and processing area. Jian does not automatically represent all Jilin, and provincial shares cannot be allocated to one Jian company.

Fresh ginseng has high moisture and loses weight or spoils quickly; washing followed by steaming or direct drying creates different products and colours. Trimming, grading and drying mean fresh input cannot equal dried output. Mixing parcels before drying also weakens origin and age traceability.

Primary-processing records list fresh weight, visual grade, treatment, equipment, time and temperature, drying endpoint, dry weight and moisture. Small roots, rootlets and rejected material are weighed separately with defined uses. A finished lot blended from several cultivation lots retains each input proportion.

  • The fresh-to-dry conversion retains yield and moisture.

04 · Yisheng Identity Does Not Cover Every Ginseng Product Category

Jian industry information and a company site establish region and entity separately.

Jian industry information describes a local cultivation and processing base, while the Yisheng website identifies Jilin Jian Yisheng Pharmaceutical as an operator. Together they place the company in an important ginseng region. They do not allocate all Jian output, companies or regional resources to Yisheng.

Ginseng material can enter ordinary food, health food, medicine or personal-care products, each with different materials, production authorisations, labels and permitted statements. Pharmaceutical in a company name does not make every item a medicine. A product category follows approval or filing, standard, ingredients and actual use.

A Yisheng engagement uses the full item name and approval, filing or licence number to establish category before checking maker, site, species, amount, size and storage. Medicines and health foods use only authorised labels and instructions, with no efficacy inferred from provincial value. A different licence holder or plant triggers renewed review.

  • Foods, health foods and medicines use their own authorisations and labels.

05 · Yisheng and Kangmei Xinkaihe Cannot Share Origin or Product Evidence

Operation in Jilin establishes no material, outsourcing or sales relationship.

Corporate information identifies Yisheng and Kangmei Xinkaihe independently. Their connection to Jilin ginseng shows several operators in one industry. Nothing in the two profiles jointly discloses fresh-root supply, contract processing, shared brands or common channels.

A ginseng origin statement may refer to cultivation, primary processing or manufacturing address, and the three are not interchangeable. Material moving to another company for processing retains parcel, age and weight-conversion records. Jilin or Jian language on both sides does not prove roots from one field lot.

Each supplier separately provides its origin rule, material receipt, processing record, authorisations and label sample. If one claims processing by the other, contract, lot and finished-product maker must match in documents from both sides. Samples and company files stay separate without reconcilable records.

  • Each confirms field source, process lot, authorisation and contracting entity.

06 · Kangmei Xinkaihe and Binghua Need Item-Level Scope Checks

Company sites are contact points, not a shared product catalogue.

The Kangmei Xinkaihe and Binghua websites separately identify two Jilin ginseng or traditional-medicine-related operators. Company names suggest possible direction but do not fully list current products, active operation or licence scope. Parallel appearance proves no investment, supply or technical cooperation.

Whole dried roots, slices, powder, extracts and compound products differ in particle size, moisture, composition, contamination risk and use. Testing one root lot does not cover every downstream product, and an extract specification cannot recover fresh-root input. Quality standards stay separate when products cross food and medicine categories.

Each enquiry states product category, material form, species, origin, age, process, characteristic component or grade, package and destination. Test reports match the actual maker, item and lot. Price comparison includes loss, testing, minimum quantity and storage rather than ranking unlike forms by price per kilogram.

  • Raw roots, herbal pieces, foods and other products are accepted separately.

07 · One Binghua Item Cannot Carry Jilin Output Shares

Provincial scale and company product identity use separate evidence.

The Binghua website identifies a Jilin operator, while provincial investment information records comprehensive value, output shares and product development. Together they describe the company environment. Roughly 60 percent of Chinese output, 40 percent of world output and more than 3,000 products do not belong to Binghua alone.

Regional scale can improve access to materials and services, but does not guarantee species, age, residues, composition or storage for every lot. A large output share is not company market share and cannot support disease-prevention or treatment statements. Permitted claims depend on category and authorised labelling.

A Binghua product file separately records company identity, manufacturing authorisation, category, material lot, label version and tests. Health-related wording is checked sentence by sentence against applicable rules and approved content, with no channel expansion. Provincial figures remain industry context and never become item efficacy or quality proof.

  • Marketing cannot turn regional share into item quality or efficacy.

08 · Close Jilin Procurement around One Ginseng Root Lot

Field lot, primary process, formula, testing and finished code remain continuous.

Jilin ginseng value above RMB 80 billion and substantial output shares show a deep industry base, while high-quality development policy provides a standardisation direction. The region offers cultivation, processing and testing partners. Every order still resolves to one species, material lot, product category and responsible entity.

The raw-material specification fixes species, origin, parcel or supply lot, age, fresh or dry state, process, moisture and visual grade. Cutting, milling or extraction records input weight, screening, by-products, solvent or temperature, yield and blending. Formula and package use controlled versions, and a new source triggers renewed identity, contaminant and characteristic-component review.

First-lot receiving checks maker, licence or approval number, finished code, label, net content, storage and remaining life and applies tests for the product category. A trace exercise moves from one retail pack back to its parcel and primary-processing lot and then locates other stock. Procurement does not expand when species, origin or regulatory identity fails to close.

  • Confirm regulatory category before process and acceptance tests.

Sources and reading notes

The comprehensive value above RMB 80 billion in 2024 and the 2026 measures of roughly 60 percent of Chinese output, about 40 percent of world output and more than 3,000 developed products all use a Jilin industry scope and do not share one year. They cannot be allocated to Yisheng, Kangmei Xinkaihe or Binghua or used as efficacy evidence.

  • 2024 comprehensive output: RMB 80bn+
  • Jilin share of China ginseng output: ~60%
  • Jilin share of global ginseng output: ~40%

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

  • Binghua Traditional Medicine — Jilin Provincial Government documents the local base of Jilin Ginseng Health Products. The company’s official site describes related products or services and an operating presence in Changbai Mountain ginseng region, Jilin.
  • Xinkaihe — Jilin Provincial Government documents the local base of Jilin Ginseng Health Products. The company’s official site describes related products or services and an operating presence in Changbai Mountain ginseng region, Jilin.
  • Yisheng Pharmaceutical — Jilin Provincial Government documents the local base of Jilin Ginseng Health Products. The company’s official site describes related products or services and an operating presence in Changbai Mountain ginseng region, Jilin.
  • Request a company-record correction or removal — Requests are reviewed by a person, handled promptly after verification, free of charge and not tied to commercial cooperation.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.